• Dr Richard Davis appointed in the newly created role of Chief Executive Officer
• Industry recognised clinical expert, Dr Marie Lindner appointed as a non-executive to the Board of Directorsbr>
• Trino Therapeutics lead candidate, PH46A, advances in an extended Phase I clinical trial br>
DUBLIN, Ireland. 3rd November 2014. Trino Therapeutics, a clinical stage development company today announced the appointments of Richard Davis, PhD., to the newly created position of chief executive officer and Marie Lindner, MD., as a non-executive director to the Board of Directors.br>
Trino’s co-founder and managing director, Prof. Neil Frankish commented “Trino recognises that the wealth of experience brought by both Richard and Marie will significantly help to realize the full potential of PH46A in addressing the unmet medical needs of patients with inflammatory bowel disease”.br>
Dr Davis joins from Wellcome Trusts Investment Division, where he managed direct investments in private and public pharmaceutical and life science companies, as well as those in sector-focused venture capital and private equity funds. He joins with a successful track record in raising multiple financings and achieving exits for portfolio companies via both acquisition and IPO. Previously he gained 12 years’ experience in investing and managing drug development assets arising from academia, private and public biotech companies.br>
Dr Marie Lindner joined the Trino Board as a Non-Executive Director in March 2014. A distinguished medical gastroenterologist, Dr Lindner is currently Global Program Head, Strategic Partnership Team at Novartis in Basel, Switzerland. Prior to this role she was a Senior Director of Scientific Licensing for Shire Pharmaceuticals, and formerly a Venture Partner at BioAdvance working closely with therapeutic-focused portfolio companies on business, regulatory and clinical strategy. Before this Dr Lindner held management roles in Isolagen Therapeutics, Inc., BTG plc and Elan Corp and executive roles at SmithKline Beecham and Rhône-Poulenc Rorer.br>
Endsbr>
Contactbr>
Dr Richard Davis, Chief Executive Officerbr>
T: +353 1 531 0056br>
E: rdavis@trinotherapeutics.com br>
About Trino Therapeuticsbr>
Ireland’s Trino Therapeutics is a privately held biotech company focused on developing oral small molecules for the treatment and management of inflammatory bowel disease (IBD) and other inflammatory indications. Trino was initially spun out of Trinity College Dublin with seed investment and support from Enterprise Ireland. In 2013 the company announced it had closed the third tranche of the €9m Series ‘A’ financing led by Fountain Healthcare Partners (Dublin, Ireland) and Wellcome Trust (UK) to advance its lead candidate through preclinical development and early clinical development. Its first orally active candidate, PH46A is currently under evaluation in Phase I clinical trials. For more information please visit www.trinotherapeutics.com br>
About Fountain Healthcare Partnersbr>
Headquartered in Dublin, Fountain Healthcare Partners is one of Ireland's largest dedicated life science venture capital fund. Specific areas of interest to Fountain are specialty pharmaceuticals, biotechnology, medical devices and diagnostics. For more information please visit www.fh-partners.com. br>
About Wellcome Trustbr>
The Wellcome Trust is the world’s second-highest-spending charitable foundation, dedicated to achieving extraordinary improvements in human and animal health. It was created in 1936 on the death of Sir Henry Wellcome and is independent of both political and commercial interests. The Trust’s breadth of support includes public engagement, education and the application of research to improve health. For more information, please visit www.wellcome.ac.uk br>
Help employers find you! Check out all the jobs and post your resume.
• Industry recognised clinical expert, Dr Marie Lindner appointed as a non-executive to the Board of Directorsbr>
• Trino Therapeutics lead candidate, PH46A, advances in an extended Phase I clinical trial br>
DUBLIN, Ireland. 3rd November 2014. Trino Therapeutics, a clinical stage development company today announced the appointments of Richard Davis, PhD., to the newly created position of chief executive officer and Marie Lindner, MD., as a non-executive director to the Board of Directors.br>
Trino’s co-founder and managing director, Prof. Neil Frankish commented “Trino recognises that the wealth of experience brought by both Richard and Marie will significantly help to realize the full potential of PH46A in addressing the unmet medical needs of patients with inflammatory bowel disease”.br>
Dr Davis joins from Wellcome Trusts Investment Division, where he managed direct investments in private and public pharmaceutical and life science companies, as well as those in sector-focused venture capital and private equity funds. He joins with a successful track record in raising multiple financings and achieving exits for portfolio companies via both acquisition and IPO. Previously he gained 12 years’ experience in investing and managing drug development assets arising from academia, private and public biotech companies.br>
Dr Marie Lindner joined the Trino Board as a Non-Executive Director in March 2014. A distinguished medical gastroenterologist, Dr Lindner is currently Global Program Head, Strategic Partnership Team at Novartis in Basel, Switzerland. Prior to this role she was a Senior Director of Scientific Licensing for Shire Pharmaceuticals, and formerly a Venture Partner at BioAdvance working closely with therapeutic-focused portfolio companies on business, regulatory and clinical strategy. Before this Dr Lindner held management roles in Isolagen Therapeutics, Inc., BTG plc and Elan Corp and executive roles at SmithKline Beecham and Rhône-Poulenc Rorer.br>
Endsbr>
Contactbr>
Dr Richard Davis, Chief Executive Officerbr>
T: +353 1 531 0056br>
E: rdavis@trinotherapeutics.com br>
About Trino Therapeuticsbr>
Ireland’s Trino Therapeutics is a privately held biotech company focused on developing oral small molecules for the treatment and management of inflammatory bowel disease (IBD) and other inflammatory indications. Trino was initially spun out of Trinity College Dublin with seed investment and support from Enterprise Ireland. In 2013 the company announced it had closed the third tranche of the €9m Series ‘A’ financing led by Fountain Healthcare Partners (Dublin, Ireland) and Wellcome Trust (UK) to advance its lead candidate through preclinical development and early clinical development. Its first orally active candidate, PH46A is currently under evaluation in Phase I clinical trials. For more information please visit www.trinotherapeutics.com br>
About Fountain Healthcare Partnersbr>
Headquartered in Dublin, Fountain Healthcare Partners is one of Ireland's largest dedicated life science venture capital fund. Specific areas of interest to Fountain are specialty pharmaceuticals, biotechnology, medical devices and diagnostics. For more information please visit www.fh-partners.com. br>
About Wellcome Trustbr>
The Wellcome Trust is the world’s second-highest-spending charitable foundation, dedicated to achieving extraordinary improvements in human and animal health. It was created in 1936 on the death of Sir Henry Wellcome and is independent of both political and commercial interests. The Trust’s breadth of support includes public engagement, education and the application of research to improve health. For more information, please visit www.wellcome.ac.uk br>
Help employers find you! Check out all the jobs and post your resume.
